Appetite-suppressant drugs and the risk of primary pulmonary hypertension. International Primary Pulmonary Hypertension Study Group. - Test2 - elhamkhani - TriplyDB

Appetite-suppressant drugs and the risk of primary pulmonary hypertension. International Primary Pulmonary Hypertension Study Group.

Appetite-suppressant drugs and the risk of primary pulmonary hypertension. International Primary Pulmonary Hypertension Study Group.

http://www.wikidata.org/entity/Q34062887

about

Benfluorex and unexplained valvular heart disease: a case-control study Valvular regurgitation and surgery associated with fenfluramine use: an analysis of 5743 individuals 5-HT2B receptor antagonists inhibit fibrosis and protect from RV heart failure Pharmacotherapies for obesity: past, current, and future therapies Long-term pharmacotherapy for obesity and overweight Expressing the magnitude of adverse effects in case-control studies: "the number of patients needed to be treated for one additional patient to be harmed"Dual dopamine/serotonin releasers: potential treatment agents for stimulant addiction Pharmacological targeting of the serotonergic system for the treatment of obesity Regulatory challenges for new drugs to treat obesity and comorbid metabolic disorders New insights into the pathogenesis and treatment of primary pulmonary hypertension Anorexigen-induced pulmonary hypertension and the serotonin (5-HT) hypothesis: lessons for the future in pathogenesis Pulmonary hypertension in the elderly: a different disease?Challenges and Current Efforts in the Development of Biomarkers for Chronic Inflammatory and Remodeling Conditions of the Lungs Low-dose fenfluramine in the treatment of neurologic disorders: experience in Dravet syndrome The genetics of pulmonary arterial hypertension Transglutaminase 2-mediated serotonylation in pulmonary hypertension SM22alpha-targeted deletion of bone morphogenetic protein receptor 1A in mice impairs cardiac and vascular development, and influences organogenesis Linking a serotonin transporter polymorphism to vascular smooth muscle proliferation in patients with primary pulmonary hypertension Serotonin transporter overexpression is responsible for pulmonary artery smooth muscle hyperplasia in primary pulmonary hypertension The effect of fenfluramine on the pulmonary disposition of 5-hydroxytryptamine in the isolated perfused rat lung: a comparison with chlorphentermine Pulmonary arterial hypertension associated with interferon therapy: a population-based study Lisdexamfetamine in the treatment of moderate-to-severe binge eating disorder in adults: systematic review and exploratory meta-analysis of publicly available placebo-controlled, randomized clinical trials New and emerging drug molecules against obesity.Inhaled iloprost in pulmonary arterial hypertension.Recent trends in pulmonary arterial hypertension How the serotonin story is being rewritten by new gene-based discoveries principally related to SLC6A4, the serotonin transporter gene, which functions to influence all cellular serotonin systems.A brief overview of mouse models of pulmonary arterial hypertension: problems and prospects.Clinical presentation, differential diagnosis, and vasodilator testing of pulmonary hypertension.Pulmonary hypertension: diagnosis and management Pulmonary hypertension for primary care providers Gene expression in lungs of mice lacking the 5-hydroxytryptamine transporter gene.Periodic health examination, 1999 update: 1. Detection, prevention and treatment of obesity. Canadian Task Force on Preventive Health Care How to manage primary pulmonary hypertension. Giving hope to patients with a life-threatening illness.Sex differences in the pulmonary circulation: implications for pulmonary hypertension Acute oxygen-sensing mechanisms.Effective management of obesity Accelerated publication versus usual publication in 2 leading medical journals Role of serotonin in the pathogenesis of acute and chronic pulmonary hypertension Drugs and dilated cardiomyopathies: A case/noncase study in the French PharmacoVigilance Database.Helping an obese patient make informed choices.

P2860

Q21091138-7462AD07-42F3-43C4-9CCE-1938AD12FE5C Q21245270-C5ED04D5-7FC6-40FA-B793-C872FEF28653 Q21284504-033D14DA-DAE1-4372-934C-CB9C0742CE22 Q21296814-24F9C7E9-9478-46D3-9F3C-E47143413FF0 Q24247723-3A6186A5-25BC-4100-B00E-8210F88CAA82 Q24527283-BECB4838-28BF-4109-8928-6CD2E882BE47 Q24641896-F271D401-3415-48EC-9690-35ACDF829FB6 Q24658013-3B9B9CF2-75AD-4C00-B3F8-0D38957D6072 Q24658031-C0555792-5439-4AD7-8E18-9EEB45266FF4 Q24679149-29CA079D-4BE2-445C-90F0-0C7EEE92B090 Q24799173-3951CB38-413A-4EDC-BFCC-B370F2A4E93D Q26749453-E5FC43A8-2072-4564-B638-80DBC2C08C70 Q26766294-433C68F8-3185-42D0-81BC-A285D3C1FCEF Q26776222-35227E6F-3BD0-414E-BEE5-08DE77BB7AC7 Q27027507-C736B478-8624-46F7-BBE7-7F56D2F42F32 Q27027862-0DBC7582-6629-4B56-94CC-A12A23840C5B Q28118787-63390F37-B0AF-49FD-B46F-16787830E169 Q28361811-F23648F9-AC47-4346-BA94-4F60D3E591B5 Q28361826-8AA9FE44-BB9E-49B8-8F4F-F8431A6D0DC7 Q28373184-6A2FB906-576E-4C86-8D8D-C8FA07798AA3 Q28468304-FAF9D776-CD1C-4A17-AD20-4BBA44EFA435 Q28553322-62F62A58-8B86-4FE5-8DDD-ADE06CE570B8 Q30353872-89D9B122-4AEA-4F0A-A72B-C3EA38C08404 Q30437211-C204C018-0C33-44AC-9288-E33313F0380A Q30475192-ECF29904-45C4-4D16-9629-6EC038F00938 Q30485725-2397512D-91E6-49F3-BEBE-84013B6A0317 Q30544892-BD24C89E-F53B-4C04-AC7B-9839737C4154 Q33155179-A92E9960-52B3-44F2-832D-50D13AFD4E7D Q33157071-ED537D14-96AD-44EE-8136-C39C79AC7BB8 Q33160056-7B6D841E-0429-4295-9208-F724A968FE11 Q33442097-F49433E4-F663-400E-A0E0-C97B3FA50184 Q33542344-BA11E024-C453-4BAF-A75E-76D6A580AFEB Q33543487-F71DE050-B4FB-43B0-AEE7-A180701FC5AC Q33568826-892901B6-4958-4BD1-BDE6-6E2FE1B3E443 Q33577287-7EBB953C-861E-4391-AF65-EE58EC84F739 Q33578930-71BAB0D2-4A94-45C3-814D-D106CE6894A2 Q33609417-1F9E87D9-5DE9-4CB2-8792-DDF72D5A9749 Q33634204-5DC30315-21EC-434D-B33B-98C40937F213 Q33692818-18A001F1-CCE7-44A3-BD87-F9D1005E7530 Q33791194-1FF95BB4-C6B8-4FD9-9718-51E22F2BBD1B

P2860

Appetite-suppressant drugs and the risk of primary pulmonary hypertension. International Primary Pulmonary Hypertension Study Group.

http://www.wikidata.org/entity/Q34062887

description

1996 nî lūn-bûn

@nan

1996 թուականի Օգոստոսին հրատարակուած գիտական յօդուած

@hyw

1996 թվականի օգոստոսին հրատարակված գիտական հոդված

@hy

1996年の論文

@ja

1996年論文

@yue

1996年論文

@zh-hant

1996年論文

@zh-hk

1996年論文

@zh-mo

1996年論文

@zh-tw

1996年论文

@wuu

name

Appetite-suppressant drugs and ...... nary Hypertension Study Group.

@ast

Appetite-suppressant drugs and ...... nary Hypertension Study Group.

@en

Appetite-suppressant drugs and ...... nary Hypertension Study Group.

@nl

type

label

Appetite-suppressant drugs and ...... nary Hypertension Study Group.

@ast

Appetite-suppressant drugs and ...... nary Hypertension Study Group.

@en

Appetite-suppressant drugs and ...... nary Hypertension Study Group.

@nl

prefLabel

Appetite-suppressant drugs and ...... nary Hypertension Study Group.

@ast

Appetite-suppressant drugs and ...... nary Hypertension Study Group.

@en

Appetite-suppressant drugs and ...... nary Hypertension Study Group.

@nl

P1433

Q34062887-3EFB89BD-3869-4514-9238-4E7AB76D8331

P1476

Q34062887-E745BAEC-824C-47FE-BBA0-B8412E888E27

P2093

Q34062887-33C08C34-91DF-4F15-940F-E5586D7844CB

Q34062887-4648E554-E62C-48BD-8F10-4286A0FDF9B6

Q34062887-4A40D9D1-E47D-4D7D-AE59-A0A31DB3E9E8

Q34062887-6AE465DB-FBFF-4E2E-9031-818BCCACFADA

Q34062887-71AEBAAD-38D5-4C78-BE72-C0C7B00CC63D

Q34062887-AF64FFB4-D67C-428B-A304-01E8DCA82AB4

Q34062887-B42BA6E9-CD5C-4365-99A4-D09198748C15

Q34062887-D2F9E5E9-9EA1-4837-B50F-48B16AADCEAB

Q34062887-DE949826-0727-47C4-BA5B-3E8E2FBEB617

Q34062887-E38AD220-0CC7-4F99-A360-4362B9FEB413

P304

Q34062887-3B760174-9462-4C5E-A1C6-574B4EEFE9A5

P31

Q34062887-45355727-9491-48F9-A191-F0EADC0EBD18

P356

Q34062887-F755813C-B9FF-4CA9-A2FB-1A40979F5984

P407

Q34062887-2DA1B1E0-88B0-4B54-996A-0C7F40F38E81

P433

Q34062887-9EC5BCBD-124D-40F5-8F0B-C6981BBE41B6

P478

Q34062887-566E1EB2-21D7-463A-AEE1-97E5848064BD

P50

Q34062887-9B3351D4-5793-4662-A2A4-2232DEE84B29

P577

Q34062887-CC42094A-E344-4FC4-A519-66FDBDA03283

P698

Q34062887-D467FC61-47CA-4C80-92F7-E0482541BBD3

P921

Q34062887-50A46098-6FD5-4BEB-97DC-4ABB787FD383

Q34062887-E6021795-6526-44E9-AB69-AADA2404C16E

P356

NEJM199608293350901

P1433

The New England Journal of Medicine

P1476

Appetite-suppressant drugs and ...... nary Hypertension Study Group.

@en

P2093

B Bégaud

http://www.w3.org/2001/XMLSchema#string

C Oakley

http://www.w3.org/2001/XMLSchema#string

E Wouters

http://www.w3.org/2001/XMLSchema#string

F Brenot

http://www.w3.org/2001/XMLSchema#string

G Simonneau

http://www.w3.org/2001/XMLSchema#string

J Benichou

http://www.w3.org/2001/XMLSchema#string

L Abenhaim

http://www.w3.org/2001/XMLSchema#string

S Rich

http://www.w3.org/2001/XMLSchema#string

T Higenbottam

http://www.w3.org/2001/XMLSchema#string

X Kurz

http://www.w3.org/2001/XMLSchema#string

P304

609-616

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1056/NEJM199608293350901

http://www.w3.org/2001/XMLSchema#string

P407

P433

9

http://www.w3.org/2001/XMLSchema#string

P478

335

http://www.w3.org/2001/XMLSchema#string

P50

P577

1996-08-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

8692238

http://www.w3.org/2001/XMLSchema#string

P921

arterial hypertension